Jacob Sands is an Oncology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 149 publications with 4,258 citations (h-index 30); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
41 Burlington Mall Rd.
Lahey Clinic
Burlington, MA 01805
Telephone
916-734-7080Registry record last updated 18 Dec 2012.
Clinical trials
- SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Sponsor: Dana-Farber Cancer Institute
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Sponsor: Alliance Foundation Trials, LLC.
- A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
Sponsor: Addario Lung Cancer Medical Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202520 payments$20,662openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202510 payments$20,279openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202510 payments$15,484openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
61.3%Corticosteroid61.3%Dexamethasone100%Part D≥17 patientsNervous system
38.7%Phenothiazine38.7%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Journal of Thoracic Oncology
2025 - NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”